A promising antimicrobial hit is only the beginning. Understanding how microorganisms respond, why activity differs between strains or conditions, and how readily they may adapt can be critical to deciding what comes next.

In a new article published in the Autumn 2026 issue of International Biopharmaceutical Industry, Dr Shi-qi An and Dr Paula Yagüe of Novogene Europe explore how genomics, transcriptomics, metabolomics and metagenomics can add biological context to antimicrobial discovery.

“Rethinking Antimicrobial Discovery Through Omics” considers how well-designed omics studies can help investigate antimicrobial response, resistance and potential mechanisms of action, while supporting more informed experimental and development decisions.

Read the full article in International Biopharmaceutical Industry